Home › Compare › ACOR vs O

ACOR vs O: Dividend Comparison 2026

ACOR yields 302.57% · O yields 5.28%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 ACOR wins by $99.2K in total portfolio value
10 years
ACOR
ACOR
● Live price
302.57%
Share price
$0.66
Annual div
$2.00
5Y div CAGR
-50%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$133.5K
Annual income
$200.19
Full ACOR calculator →
O
Realty Income Corporation
● Live price
5.28%
Share price
$61.15
Annual div
$3.23
5Y div CAGR
15.1%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$34.2K
Annual income
$5,102.74
Full O calculator →

Portfolio growth — ACOR vs O

📍 ACOR pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodACORO
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, ACOR + O cover 0 of 12 months — good coverage

Jan
—
Feb
—
Mar
—
Apr
—
May
—
Jun
—
Jul
—
Aug
—
Sep
—
Oct
—
Nov
—
Dec
—
ACOR pays
O pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

ACOR
Annual income on $10K today (after 15% tax)
$25,718.61/yr
After 10yr DRIP, annual income (after tax)
$170.16/yr
O
Annual income on $10K today (after 15% tax)
$449.12/yr
After 10yr DRIP, annual income (after tax)
$4,337.33/yr
At 15% tax rate, O beats the other by $4,167.17/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of ACOR + O for your $10,000?

ACOR: 50%O: 50%
100% O50/50100% ACOR
Portfolio after 10yr
$83.9K
Annual income
$2,651.46/yr
Blended yield
3.16%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on O right now

ACOR
Analyst Ratings
5
Buy
11
Hold
3
Sell
Consensus: Hold
Altman Z
-32.7
Piotroski
3/9
O
Analyst Ratings
13
Buy
18
Hold
3
Sell
Consensus: Hold
Price Target
$64.00
+4.7% upside vs current
Range: $60.00 — $69.00
Altman Z
1.0
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

ACOR buys
0
O buys
0
No recent congressional trades found for ACOR or O in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricACORO
Forward yield302.57% ✓5.28%
Annual dividend / share$2.00$3.23 ✓
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR-50%15.1% ✓
Portfolio after 10y$133.5K ✓$34.2K
Annual income after 10y$200.19$5,102.74 ✓
Total dividends collected$70.1K ✓$20.7K
Payment frequencyquarterlymonthly
SectorStockREIT
Analyst consensusHoldHold

Year-by-year: ACOR vs O ($10,000, DRIP)

YearACOR PortfolioACOR Income/yrO PortfolioO Income/yrGap
1← crossover$25,829$15,128.59$10,818$608.16+$15.0K → ACOR
2$45,896$18,259.36$11,787$741.68+$34.1K → ACOR
3$64,270$15,161.61$12,946$911.00+$51.3K → ACOR
4$78,690$9,921.27$14,345$1,127.94+$64.3K → ACOR
5$89,875$5,676.30$16,056$1,409.05+$73.8K → ACOR
6$99,196$3,029.49$18,171$1,777.83+$81.0K → ACOR
7$107,702$1,562.46$20,820$2,268.21+$86.9K → ACOR
8$116,034$792.73$24,188$2,929.90+$91.8K → ACOR
9$124,555$399.09$28,533$3,837.11+$96.0K → ACOR
10$133,474$200.19$34,235$5,102.74+$99.2K → ACOR

ACOR vs O: Complete Analysis 2026

ACOR — Stock

Acorda Therapeutics, Inc., a biopharmaceutical company, develops and commercializes therapies for neurological disorders in the United States. The company markets Ampyra (dalfampridine), an oral drug to improve walking in patients with multiple sclerosis (MS); and Inbrija for the treatment of OFF periods in Parkinson's disease in Europe. It also markets Ampyra as Fampyra in Europe, Asia, and the Americas. In addition, the company develops ARCUS product for the treatment of acute migrain; rHIgM22, which has completed Phase I clinical trial for the treatment of MS; and Cimaglermin alfa for heart failure patients. The company has collaboration and license agreement with Biogen Inc. for the development and commercialization of Ampyra. Acorda Therapeutics, Inc. was incorporated in 1995 and is headquartered in Ardsley, New York.

Full ACOR Calculator →

O — REIT

Realty Income, The Monthly Dividend Company, is an S&P 500 company dedicated to providing stockholders with dependable monthly income. The company is structured as a REIT, and its monthly dividends are supported by the cash flow from over 6,500 real estate properties owned under long-term lease agreements with our commercial clients. To date, the company has declared 608 consecutive common stock monthly dividends throughout its 52-year operating history and increased the dividend 109 times since Realty Income's public listing in 1994 (NYSE: O). The company is a member of the S&P 500 Dividend Aristocrats index. Additional information about the company can be obtained from the corporate website at www.realtyincome.com.

Full O Calculator →
📬

Get this ACOR vs O comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

ACOR vs SCHDACOR vs JEPIACOR vs KOACOR vs MAINACOR vs STAGACOR vs ADCACOR vs NNNACOR vs VICI

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.